Netazepide, a Gastrin Receptor Antagonist, Normalises Tumour Biomarkers and Causes Regression of Type 1 Gastric Neuroendocrine Tumours in a Nonrandomised Trial of Patients with Chronic Atrophic Gastritis

• Andrew R. Moore,

  Affiliations Department of Gastroenterology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom, Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom

  ⨯
• Malcolm Boyce,

  Affiliation Hammersmith Medicines Research, London, United Kingdom

  ⨯
• Islay A. Steele,

  Affiliation Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom

  ⨯
• Fiona Campbell,

  Affiliation Department of Pathology, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom

  ⨯
• Andrea Varro,

  Affiliation Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom

  ⨯
• D. Mark Pritchard

  * E-mail: mark.pritchard@liverpool.ac.uk

  Affiliation Department of Gastroenterology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom

  ⨯